Destiny releases pivotal phase 2 data involving XF-73 nasal gel by John Pinching | Mar 24, 2023 | News | 0 Study shows significant reduction of nasal S. aureus in cardiac surgery patients before surgery Read More
Destiny Pharma listed on London Stock Exchange by Selina McKee | Sep 5, 2017 | News | 0 Brighton, UK-based Destiny Pharma has been successfully listed shares on London Stock Exchange with a market capitalisation of £65.4 million, marking the second biotech company to float this year in the UK. Read More